By Arjun Jayadeva, The HinduThe Hindu | February 9, 2017
The Trans-Pacific Partnership was dead long before Donald Trump signed his executive order. But its damaging aspects, like stringent IP provisions, have just migrated to other agreements
U.S. President Donald Trump’s first week in office was, to put it mildly, tumultuous. In the midst of the complete upending of normal politics, reflected by developments like the travel ban on seven Muslim-majority countries and the promotion of ‘alternative facts’, it is easy to forget that one of his first acts as President was to veto U.S. participation in the Trans-Pacific Partnership (TPP), a trade deal among 12 Pacific economies that was a decade in the making. Continue reading
It is important to note that the EU proposals on IP are TRIPS-plus in multiple regards and would surely reduce policy space in Indonesia and negatively impact access to affordable medicines. Even a preliminary review of the proposal reveals:
- A requirement to make all reasonable efforts to abide with the WIPO Patent Law Treaty, which risks enshrining lower standards of patentability.
- Mandatory patent term extensions to compensate for regulatory delay in granting marketing approval of medicines with a proposed minimum 15 year term of effective patent coverage.
Picture Courtesy: TAC Twitter
Positive Malaysian Treatment Access & Advocacy Group (MTAAG+) calls on the Malaysian government to reject trade and investment agreement provisions that threaten access to affordable medicines.
MTAAG+ asserts the need to make its position and demand known because of the confusion that has arisen surrounding US President Donald Trump’s Executive Order for his government to formally withdraw from the Trans-Pacific Partnership Agreement (TPPA). Continue reading
“The Australian Fair Trade and Investment Network of 60 community organisations welcomes the conclusion of the ALP members of the Senate inquiry into the Trans-Pacific Partnership (TPP) that the implementing legislation should not proceed but be deferred,” AFTINET Convener Dr Patricia Ranald said today. Continue reading
Tuesday, 7th February 2017 –* Swiss multinational company Roche faced global condemnation today from women living with cancer, families of people with cancer, activists, scientists, researchers and health professionals from across the world. They highlighted the immoral and unconscionable tactics employed by Roche across the developed and developing world. Roche’s greed is preventing women from accessing affordable versions of trastuzumab, an essential medicine used in the treatment of breast cancer.